UBS maintains Viavi Solutions at Neutral, lowers price target to $33 from $44
UBS kept its Neutral rating on Viavi Solutions but cut its price target to $33 from $44, a 25% reduction. This suggests a 25.5% upside from the Nov 5 closing price of $26.30, according to UBS.
How this was made

The 30-second read
Why it matters
The downgrade could trigger short‑term selling pressure, especially among momentum traders.
Market read
A modest analyst target cut for a small‑cap stock; limited broader market impact.
What to watch
Potential upside from upcoming product launches or new service contracts not captured in the analyst note.
Background
UBS analyst maintains a neutral rating but reduces the price target, indicating a less optimistic outlook for Viavi Solutions.
Ticker impact
UBS lowered its price target for Viavi Solutions from $44 to $33, a 25% reduction.
potential downward pressure as the market prices in the lower target
Analyst target reductions often lead to short-term sell pressure, especially for small‑cap stocks.
Market effects
Minimal; the downgrade is specific to Viavi and does not signal broader sector trends.
U.S. market focus; no regional spillover.
Low; limited to investors tracking Viavi Solutions.
Counterpoint
The target cut may be overly pessimistic if recent contract wins are not yet reflected in the price.
Key entities
- CompanyViavi Solutions
Provider of network testing, monitoring, and assurance solutions.
- AnalystUBS
Investment bank issuing the rating and target change.



